Email

Print

Tweet

Digg!

Del.icio.us

Dallas, TX and New York, NY, November 11, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it will be presenting a poster today at the 10th Annual Diabetes Technology Meeting, entitled, “Preclinical Studies with Cobalamin™ Nanoparticles for Oral Drug Delivery of Insulin.”  The poster reviews the progress made by Access scientists in developing its proprietary oral insulin formulation. Access recently rebranded its oral drug delivery technology as CobOral^TM to reflect the advances made with the technology platform.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Patients Experienced 52% Reduction in Pain and Oral Discomfort; MuGard’s Ready-to-Use Formulation Well Accepted By 86% of Patients

DALLAS, TX and NEW YORK, NY, October 11, 2010

Access Pharmaceuticals, Inc. (OTC BB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year’s European Society of Medical Oncology Conference in Milan, Italy.   Some of the findings reported in the ESMO presentation included:

• MuGard provided a significant improvement and/or stabilization of oral mucositis lesions and symptoms of oral mucositis (OM) in more than 75% of cancer patients treated with radiotherapy/chemotherapy;

• Patients reported a 52% significant reduction in oral discomfort (oral pain and swallowing ability) in patients with pre-existing lesions of OM, and reported a substantial reduction in the use of pain medication;

• MuGard has a ready-to-use formulation that is well accepted by 86% of patients, as reported in this assessment program;

• No MuGard-related adverse reactions have been identified in clinical practice;

• MuGard represents a valuable therapeutic option in the treatment and prevention of OM in cancer patients undergoing radio/chemotherapy.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Proof-of-Principle Data for Proprietary CobaCyte™ Platform in siRNA

Dallas, TX and New York, NY, September 29, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.  As a result of the continued advancements made with its Cobalamin program, Access rebranded the targeted-drug delivery technology as CobaCyte™; and submitted additional patent applications for its improved CobaCyte formulations, including siRNA compositions.

Over the past months, Access’ CobaCyte siRNA application has shown significant promise.  In an in vitro siRNA transfection dose-response study, Access’ CobaCyte nanoparticle carriers loaded with an apoptosis-inducing siRNA molecule showed transfection activity in hard-to-transfect cell lines with potentially better toxicity profiles compared to other reagents. Further studies including in vivo gene-knockdown studies are planned. Additionally, Access has initiated a program whereby proprietary formulations of currently marketed chemotherapies will be developed and tested to assess CobaCyte’s ability to enhance drug pharmacokinetics and pharmacodynamics.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

MuGard Clinical Experience Reflects Delayed Onset, Significant Reduction in Pain, and Ease-of-Use in the Management of Oral Mucositis and Stomatitis

DALLAS, TX and New York, NY June 24, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy. To date, clinical experience shows that MuGard provides significant clinical benefit and is effective in the management of oral mucositis/stomatitis as well as other conditions of the oral cavity involving erythema.  Key points from the poster include:
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Cobalamin Seen as Broadly Applicable for Oral Delivery of Many Large Molecule Drugs Now Administered by Injection

Dallas, TX, March 11, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies.  The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access’ Cobalamin™ Oral Drug Delivery Technology.

Read more »

Email

Print

Tweet

Digg!

Del.icio.us

DALLAS, TX, January 19, 2010

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body’s natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a “Trojan horse” mechanism. Access has focused its Cobalamin product development program on the oral delivery of insulin and human growth hormone, two peptides which currently can only be given by injection. A new Cobalamin-coated insulin-containing nanoparticle formulation delivered orally provided a pharmacological response (lowering of blood glucose levels in an animal model of diabetes) greater than 80% of that achieved by insulin delivered subcutaneously. This represents a substantial oral bioavailability, indicating that this formulation has potential for clinical development and ultimate commercialization. Adaptation of this technology has provided a Cobalamin human growth hormone formulation that has demonstrated good efficacy, represented by more than 25% improvement in weight gain, when given orally in an established animal model. Access continues to move both products towards clinical development, and plans to submit an additional patent application to protect the improvements to the technology. Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Health care professional and patient feedback very positive

DALLAS, TX, December 3, 2009

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. MuGard is commercially launched by Access’ partner, SpePharm, in six European countries, including the UK, Germany, Italy, Norway, Greece and Sweden. Access is conducting pre-marketing activities, including ramping of commercial production, with the goal of a commercial launch in 1H 2010 in the US. MuGard was granted the CE mark certification in Europe in late 2008 with the labeling “prevention and management of the lesions and symptoms of oral mucositis.”  Key findings and feedback from SpePharm’s ongoing commercial launch and patient assessment project include:
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Finalizing plans for combination studies in liver, pancreatic and ovarian cancers

Dallas, TX September 10, 2009

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), provided an update today on the Company’s clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.  Access’ clinical development team recently met with its partners Aosaikang Medicinal Group (ASK) in Nanjing, China and JCOM, Ltd. (“JCOM”) in Seoul, Korea, together with key opinion leaders in oncology indications to discuss the protocols for the three planned ProLindac combination studies.  Access and its partners are finalizing development plans and protocols for clinical trials strategically designed to examine ProLindac in combination with gemcitabine and/or taxol in hepatocellular carcinoma (a form of liver cancer), pancreatic cancer and recurrent ovarian cancer.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

August 15, 2009

BioMedReports.com‘s Mike Havrilla recently posted a new article and 19-page report on Access Pharmaceuticals, Inc. following the filing of the Company’s quarterly report on August 13, 2009 and Havrilla’s recent Q&A with the Company’s President and CEO, Jeffrey B. Davis.

The report features information on:

• Key financial metrics
• Near, intermediate and long-term catalysts for growth
• Post-marketing study results for MuGard
• North American commercialization strategy for MuGard
• MuGard launch in Asia
• Licensing discussions for Cobalamin
• Prolindac & Thiarabine clinical development

Havrilla’s report projects positive operating cash flow by mid-2010 or earlier depending on MuGard sales, post-marketing study results, and clinical experience. However, my earnings model does not even account for expected upfront licensing and clinical milestone payments for the Company’s cobalamin drug delivery technology, thiarabine, ProLindac, or earlier stage compounds, which have the added potential for $100M in licensing deals (upfront + milestone payments and royalties) for oral basal insulin product, oral hGH, ProLindac, and thiarabine within the next 12-18 months (with $20-30M possible in upfront payments from such deals).

This report contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access’ plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Email

Print

Tweet

Digg!

Del.icio.us

Enrolling Ovarian Cancer Patients in France; Finalizing Clinical Trial Programs with Partners in China and Korea

DALLAS, TX, August 3, 2009

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), provided an update today on its clinical development strategy for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumors in human clinical studies.  Access has commenced a new clinical study of ProLindac in France. The study will examine dose levels and regimens of ProLindac monotherapy in cancer patients, provide additional data to support design of combinations studies, and extend the safety database. Two ovarian cancer patients have been enrolled in the study to date, and it is anticipated 6 to 12 patients will be enrolled this year in advance of enrolling patients in trial evaluating ProLindac in combination with other chemotherapies. Access recently announced data from a recurrent ovarian cancer trial that showed that ProLindac was more active than currently available platinum drugs in that patient population, and that the drug was very well tolerated.
Read more »